Pidilizumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Pidilizumab
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target PD-1
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
Formula C6424H9920N1704O2002S48
Molar mass 147.43 kg/mol

Pidilizumab (formerly CT-011) is a monoclonal antibody being developed by Medivation for the treatment of cancer and infectious diseases.[1][2] Pidilizumab was originally thought to bind to the PD-1 immune checkpoint molecule, but this is currently uncertain.[3] Pidilizumab causes in the attenuation of apoptotic processes in lymphocytes, primarily effector/memory T cells.

Clinical trials[edit]

It had encouraging results by 2011 from phase II clinical trials for diffuse large B-cell lymphoma.[4] A phase II open-label study in combination for relapsed follicular lymphoma found good results compared to usual response rates. An add-on trial for multiple myeloma is ongoing.[5]

References[edit]

  1. ^ Westin; et al. (2014). "Safety and Activity of PD1 Blockade by Pidilizumab in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma: a Single Group, Open-label, Phase 2 Trial". Lancet Oncol. 15: 69–77. PMC 3922714Freely accessible. PMID 24332512. doi:10.1016/S1470-2045(13)70551-5. 
  2. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Pidilizumab, American Medical Association- needs login.
  3. ^ http://www.fiercebiotech.com/story/anti-pd-1-well-no-says-medivation-partial-hold-forces-halt-pivotal-cancer-s/2016-01-26
  4. ^ Teva Invests $19M More in CureTech After Positive Phase II DLBCL Data. Sept 2011
  5. ^ "Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2015-08-22.